Preliminary studies indicate that Tocilizumab (a recombinant humanized monoclonal antibody) would be able to immediately improve the clinical outcome in critically ill patients with COVID-19, due to the blockage of the febrile and inflammatory response triggered by IL-6, being an effective treatment for reducing mortality, reducing need for mechanical and noninvasive ventilation (32, 33). The gene discussed is IL6; the disease is COVID-19.